Asthma is a chronic respiratory disease that affects millions of people worldwide. It causes inflammation and narrowing of the airways, leading to symptoms such as wheezing, shortness of breath, coughing, and chest tightness. While there are many treatments available for asthma, managing symptoms can be challenging, especially for those who experience frequent exacerbations. That's where Airsupra comes in.
Airsupra is a novel combination therapy that includes albuterol and budesonide, two drugs that work together to manage asthma symptoms effectively. Albuterol is a short-acting beta2-adrenergic agonist that relaxes the smooth muscles of the airways, while budesonide is a corticosteroid that reduces inflammation. This combination makes Airsupra a rescue inhaler that can be used as needed to prevent asthma exacerbations.
ZoomRx conducted a first impression/experience survey with 30 pulmonologists, and the results were overwhelmingly positive among the aware HCPs. Out of the 30 respondents, 10 were aware of Airsupra, and 8 were highly likely to use it. Some of the open-ended responses included phrases such as "novel combination therapy," "useful for a wide subset of asthma patients," "encouraged and hopeful with the data presented," and "another drug in class that is not novel, but is a new closed combination."
The respondents also cited the convenience of Airsupra, which allows patients to manage both their symptoms and the underlying inflammation associated with asthma. One respondent noted, "having this kind of combined therapy makes it more convenient for patients." This is an important consideration because adherence to treatment is crucial for managing asthma effectively.
Another respondent stated that Airsupra would be a great option for patients who have difficulty complying with daily regimens. It would also simplify the regimen and improve compliance. This is particularly relevant because asthma management often involves multiple medications, which can be confusing and challenging for patients to keep track of.
Overall, Airsupra is an exciting new treatment option for patients with asthma. It combines two drugs that work together to manage symptoms and prevent exacerbations. The convenience of a single inhaler that can be used as needed is a significant advantage over other asthma medications, and the positive results of the first impression/experience survey suggest that it will be well-received by pulmonologists and patients alike.
